ArticleMedical hypotheses2020
Nebulized Lidocaine in COVID-19, An Hypothesis.
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- "Nebulized lidocaine for intractable cough in hospice care: a comprehensive review of efficacy, safety, and future perspectives".BMC palliative care · 2025Pooled it
- Lidocaine inhibits osteoclast activity in vitro.Bone reports · 2026Article
- Article
- Changes in the skeletal muscle transcriptome due to the intramuscular administration of lidocaine in wether lambs.Journal of animal science · 2025Article
- Article
- The Effect of Local Anesthetics on Neutrophils in the Context of Different Isolation Techniques.Biomedicines · 2023Article
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- An Approach to Acute SARS-CoV-2 Management with Complementary Neuraltherapeutic Medicine: A Case Report.Clinical medicine insights. Case reports · 2023Article
- Article
- The Effects of HBiomedicines · 2022Article
- A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.Journal of nanobiotechnology · 2022Review
- Molecular mechanisms of lidocaine.Annals of medicine and surgery (2012) · 2021Review
- A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Article
- A case report of an 18-year-old receiving nebulized lidocaine for treatment of COVID-19 cough.Heart & lung : the journal of critical careArticle
- Intravenous lidocaine infusion in a case of severe COVID-19 infection.Journal of anaesthesiology, clinical pharmacologyArticle
- Anti-inflammatory aspects of Lidocaine: a neglected therapeutic stance for COVID-19.Heart & lung : the journal of critical careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.